18F-fluoroestradiol PET imaging in a phase II trial of vorinostat to restore endocrine sensitivity in ER1/HER22 metastatic breast cancer

Lanell M. Peterson, Brenda F. Kurland, Fengting Yan, Alena Novakova-Jiresova, Vijayakrishna K. Gadi, Jennifer M. Specht, Julie R. Gralow, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Janet F. Eary, David A. Mankoff, Hannah M. Linden

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Histone deacetylase inhibitors (HDACIs) may overcome endocrine resistance in estrogen receptor-positive (ER1) metastatic breast cancer. We tested whether 18F-fluoroestradiol PET imaging would elucidate the pharmacodynamics of combination HDACIs and endocrine therapy. Methods: Patients with ER1/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer with prior clinical benefit from endocrine therapy but later progression on aromatase inhibitor (AI) therapy were given vorinostat (400 mg daily) sequentially or simultaneously with AI. 18F-fluoroestradiol PET and 18F-FDG PET scans were performed at baseline, week 2, and week 8. Results: Eight patients were treated sequentially, and then 15 simultaneously. Eight patients had stable disease at week 8, and 6 of these 8 patients had more than 6 mo of stable disease. Higher baseline 18F-fluoroestradiol uptake was associated with longer progression-free survival. 18F-fluoroestradiol uptake did not systematically increase with vorinostat exposure, indicating no change in regional ER estradiol binding, and 18F-FDG uptake did not show a significant decrease, as would have been expected with tumor regression. Conclusion: Simultaneous HDACIs and AI dosing in patients with cancer resistant to AI alone showed clinical benefit (6 or more months without progression) in 4 of 10 evaluable patients. Higher 18F-fluoroestradiol PET uptake identified patients likely to benefit from combination therapy, but vorinostat did not change ER expression at the level of detection of 18F-fluoroestradiol PET.

Original languageEnglish (US)
Pages (from-to)184-190
Number of pages7
JournalJournal of Nuclear Medicine
Issue number2
StatePublished - Feb 1 2021


  • ER1 breast cancer
  • Estrogen receptors
  • FES
  • Metastatic breast cancer
  • Vorinostat

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of '18F-fluoroestradiol PET imaging in a phase II trial of vorinostat to restore endocrine sensitivity in ER1/HER22 metastatic breast cancer'. Together they form a unique fingerprint.

Cite this